Autor/es: Clare J. Reade a,*, Lua R. Eiriksson a,b, Helen Mackay c,d
a Division of Gynecologic Oncology, University of Toronto, M700-610 University Avenue, Toronto, ON M5N 2L5, Canada
b Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Juravinski Cancer Centre, McMaster University, 699 Concession St, Hamilton, ON L8V 5C2, Canada
c Division of Medical Oncology and Hematology, University of Toronto, Canada
d Princess Margaret Hospital, 610 University Avenue, Toronto, ON M5G 2M9, Canada
Resumen: Advances in systemic therapy for vulvar SCC are urgently needed, especially in the setting of recurrent and metastatic disease. A focus on the investigation of new targeted agents is encouraged and consideration of quality of life and sexual health issues is essential. International cooperation and adaptive trial designs are required to improve outcomes for this group of traditionally under-served women.
